FDA approves an immunotherapy treatment for some patients with triple-negative breast cancer
https://www.facingourrisk.org/XRAY/FDA-approval-triple-negative-treatment
Full article: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-atezolizumab-pd-l1-positive-unresectable-locally-advanced-or-metastatic-triple-negative
The FDA approved the use of the immunotherapy drug atezolizumab (Tecentriq) in combination with the chemotherapy agent nab-paclitaxel (Abraxane) for certain patients with advanced triple-negative breast cancer. (5/26/19)
Questions To Ask Your Health Care Provider
- How do I get PD-L1 testing of my breast cancer?
- Are there other tumor biomarker tests that may help guide my treatment?
- Is the Tecentriq plus Abraxane combination treatment an option for my type of breast cancer?
- What are the side effects that I might experience with the Tecentriq plus Abraxane combination treatment?
- Are there other immunotherapy agents that may be used to treat my cancer?
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.